Description:VE-821, with the CAS number 1232410-49-9, is a small molecule that functions primarily as a selective inhibitor of the enzyme ATR (Ataxia Telangiectasia and Rad3 related protein). This compound has garnered attention in the field of cancer research due to its potential to enhance the efficacy of certain chemotherapeutic agents by targeting the DNA damage response pathways. VE-821 exhibits characteristics such as a relatively low molecular weight and specific structural features that facilitate its interaction with the ATR protein. Its selectivity for ATR over other kinases is significant, as it minimizes off-target effects, making it a valuable tool in both preclinical and clinical studies. Additionally, VE-821 has been investigated for its role in sensitizing cancer cells to radiation and other DNA-damaging agents, thereby contributing to the development of combination therapies aimed at improving treatment outcomes in various malignancies. As research continues, the full therapeutic potential and mechanisms of action of VE-821 are being explored further.
We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.
![2-Pyrazinecarboxamide, 3-amino-6-[4-(methylsulfonyl)phenyl]-N-phenyl-](https://static.cymitquimica.com/products/IN/thumb/DA000K81.jpg)
